BioNTech BNTX 深 滬
已收盤 08-07 16:00:00 美东时间
93.67
+2.480
+2.72%
華盛通- 最 高94.27
- 今 開91.90
- 成交量 142.79万股
- 最 低 91.57
- 昨 收 91.19
- 總市值 235.30亿
- 52周最高 124.00
- 市盈率 靜 --
- 換手率 0.57%
- 52周最低 79.52
- 委 比 37.10%
- 總股本 2.51亿
- 歷史最高 462.4502
- 量 比 1.04
- 振 幅 2.96%
- 歷史最低 10.9752
- 每 手 1
- 風險率 7.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pfizer Advances COVID Pipeline As Analysts Eye Upside
Pfizer ( ($PFE) ) has been popular among investors this week. Here is a recap o...
08-08 23:01
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
BioNTech Earnings Call: COVID Slide, Oncology Push
Biontech Se Sponsored Adr (($BNTX)) has held its Q2 earnings call. Read on for ...
08-06 08:22
Citigroup Maintains Buy on BioNTech, Lowers Price Target to $125
Citigroup analyst Geoff Meacham maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $130 to $125.
08-06 02:59
BioNTech 2026年第二季度财报：营收降59%，净亏损扩大
BioNTech 2026年第二季度营收1.056亿欧元，同比下降59.5%，IFRS净亏损扩大至8.208亿欧元；全年营收指引下调至16亿至19亿欧元，现金及证券投资为166.342亿欧元。
08-05 06:39
BioNTech Files Mid‑Year 2026 Interim Results and Development Update
BioNTech SE ( ($BNTX) ) has issued an announcement. On August 4, 2026, BioNTech...
08-04 19:27
BioNTech Lowers FY2026 Sales Guidance from $2.328B-$2.678B to $1.860B-$2.209B vs $2.500B Est
BioNTech (NASDAQ:BNTX) lowers FY2026 sales outlook from $2.328 billion-$2.678 billion to $1.860 billion-$2.209 billion vs $2.500 billion estimate.
08-04 18:46
BioNTech Q2 Adj. EPS $(2.58) Misses $(2.34) Estimate, Sales $122.766M Miss $182.020M Estimate
BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.58) per share which missed the analyst consensus estimate of $(2.34) by 10.26 percent. This is a 41.76 percent decrease over losses of $(1.82) per share from the same period last year. The company reported quarterly sales of $122.766 million wh...
08-04 18:45
BioNTech Names Orphan Biovitrum's Guido Oelkers As New CEO, Replacing Ugur Sahin
BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer ("CEO"), who will take office by February 1, 2027, at the latest. Succeeding Prof. Ugur Sahin, M.D., Guido Oelker...
08-03 17:14
机构：创新药海外进展将逐步进入实质性兑现阶段，2027年国内公司迎来MNC海外销售分成
8月3日，中邮证券发布了一篇医药生物行业的研究报告，报告指出，肿瘤免疫疗法持续迭代，双抗+ADC有望弯道超车。 本周我们探讨PD-（L）1/VEGF双抗+AD...
08-03 15:59
